When was DEMENEGO acquired by MONTEFIORE INVESTMENT?

DEMENEGO was acquired by MONTEFIORE INVESTMENT in 2024.

What was the revenue of DEMENEGO at the time of the deal?

The revenue of DEMENEGO at the time of the deal is estimated to be in the range of 25M - 50M EUR.

What was the EBITDA of DEMENEGO during the acquisition?

DEMENEGO's EBITDA is estimated to be in the range of 5M - 25M EUR.

How is the data for the DEMENEGO acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the DEMENEGO deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.vaminvestments.com/wp-content/uploads/2024/10/Exit_Demenego_EN.pdf

← DATABASE

Home Database Healthcare & PharmaDEMENEGO

10/2024

DEMENEGO acquired by MONTEFIORE INVESTMENT

ITALY Health Providers / Outpatient Care / Ophthalmology REV 25M - 50M EUR

Context

Montefiore Investment acquired a majority stake in Demenego from Vam Investments. This secondary LBO follows a highly successful four-year period of ownership by the seller, during which the company more than doubled its revenue and expanded its retail network from 15 to 39 stores. The new partnership is designed to build on this solid foundation, with a strategic focus on further transforming the eyewear specialist into a national leader through innovation and omnichannel development. The investment strategy emphasizes continued significant investment in digitalization, customization technology, and the expansion of the "Demenego Labs" concept. The CEO and management team remain in place to execute this next phase of growth, aiming to capitalize on the firm's reputation for visual healthcare and rapid production capabilities. The transaction highlights the group's position as a high-margin, specialized retail platform in a consolidating European market.

It is worth noting that the fund Vam Investments took control of Demenego through an LBO in 2020.

DEMENEGO, which reported an EBITDA margin of in 2023, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 1960, Demenego is a historic Italian eyewear specialist and a leading chain of specialized optical centers in North-East Italy. The company operates a network of 39 stores and employs approximately 270 people, serving a loyal database of 630,000 registered clients. Its unique business model integrates high-level healthcare services with retail excellence, featuring state-of-the-art medical equipment for vision correction in every location. A distinctive innovation is the presence of "Demenego Labs" in all sales points, which utilize interconnected digital systems to produce customized glasses in just one hour. The group offers a vast range of over 4,500 models, combining its successful private label with major international third-party brands to ensure visual well-being and a modern omnichannel shopping experience.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2023

2022

Other operations with DEMENEGO

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
09/2020	VAM INVESTMENTS	DEMENEGO	ITALY	Ophthalmology

REFERENCES

Revenue range: 25M - 50M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of DEMENEGO by MONTEFIORE INVESTMENT are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: montefiore investment